.jpg)
Demis Hassabis, winner of the 2024 Nobel Prize in Chemistry, announced that clinical trials for the first drug developed using artificial intelligence techniques will begin before the end of this year. The announcement was made during his participation in the World Economic Forum in Davos.
Hassabis, CEO of DeepMind, a subsidiary of Google, explained that his team is currently working on developing innovative solutions leveraging AI. "We are exploring all major disease areas, and I expect the first drug to emerge by the end of this year," he stated. He added, "While developing a single drug typically takes 5 to 10 years, AI can speed up this process by tenfold, which will revolutionize the healthcare sector."
Hassabis also mentioned that his startup, Isomorphic Labs, owned by Google Alphabet and specializing in drug development, is currently working on six programs in collaboration with pharmaceutical companies Eli Lilly and Novartis.
It is worth noting that the Nobel Committee announced in October that Hassabis had won the 2024 Nobel Prize in Chemistry alongside American scientists David Baker and John Jumper. Hassabis and Jumper were honored for their development of the AlphaFold2 model, which uses AI techniques to predict protein structures with exceptional accuracy. This groundbreaking model has contributed to identifying over 200 million protein structures and is available to the public, benefiting more than two million people from 190 countries.